These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 21377153

  • 21. Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles.
    Ferrari B, Pezzuto A, Barusi L, Coppola F.
    Gynecol Endocrinol; 2006 Jun; 22(6):289-96. PubMed ID: 16785153
    [Abstract] [Full Text] [Related]

  • 22. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
    Koo YA, Lee B, Park HJ, Choi J, Lee E, Choi D.
    Fertil Steril; 2009 Mar; 91(3):744-8. PubMed ID: 18321491
    [Abstract] [Full Text] [Related]

  • 23. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction.
    Yding Andersen C, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl F.
    Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles.
    Vuong TNL, Ho MT, Ha TQ, Jensen MB, Andersen CY, Humaidan P.
    J Assist Reprod Genet; 2017 Apr; 34(4):471-478. PubMed ID: 28197932
    [Abstract] [Full Text] [Related]

  • 27. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M, Maldonado LG, de Souza Bonetti TC, de Almeida Ferreira Braga DP, Iaconelli A, Borges E.
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles.
    Sahin S, Ozay A, Ergin E, Turkgeldi L, Kürüm E, Ozornek H.
    Arch Gynecol Obstet; 2015 Jan; 291(1):185-91. PubMed ID: 25078054
    [Abstract] [Full Text] [Related]

  • 30. Correlation between follicular fluid content and the results of in vitro fertilization and embryo transfer. III. Proteoglycans.
    Franchimont P, Hazee-Hagelstein MT, Hazout A, Gysen P, Salat-Baroux J, Schatz B, Demerle F.
    Biol Reprod; 1990 Aug; 43(2):183-90. PubMed ID: 2143088
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization.
    Segal S, Casper RF.
    Fertil Steril; 1992 Jun; 57(6):1254-8. PubMed ID: 1601147
    [Abstract] [Full Text] [Related]

  • 34. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
    Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA.
    Fertil Steril; 2009 Apr; 91(4 Suppl):1526-8. PubMed ID: 18990367
    [Abstract] [Full Text] [Related]

  • 35. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 36. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells.
    Khalaf M, Mittre H, Levallet J, Hanoux V, Denoual C, Herlicoviez M, Bonnamy PJ, Benhaim A.
    Reprod Biomed Online; 2010 Jul; 21(1):56-65. PubMed ID: 20457540
    [Abstract] [Full Text] [Related]

  • 37. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
    Penzias AS, Shamma FN, Gutmann JN, Seifer DB, DeCherney AH, Lavy G.
    J Assist Reprod Genet; 1992 Jun; 9(3):244-7. PubMed ID: 1525454
    [Abstract] [Full Text] [Related]

  • 38. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis.
    Chen CH, Tzeng CR, Wang PH, Liu WM, Chang HY, Chen HH, Chen CH.
    Arch Gynecol Obstet; 2018 Jul; 298(1):17-26. PubMed ID: 29600322
    [Abstract] [Full Text] [Related]

  • 39. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval.
    Celik O, Celik E, Yilmaz E, Celik N, Turkcuoglu I, Ulas M, Kumbak B, Aktan E, Ozerol I.
    Arch Gynecol Obstet; 2013 Dec; 288(6):1417-22. PubMed ID: 23801011
    [Abstract] [Full Text] [Related]

  • 40. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles.
    Onalan G, Selam B, Onalan R, Ceyhan T, Cincik M, Pabuccu R.
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar 01; 125(1):85-91. PubMed ID: 16140454
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.